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Abstract
Background: The role of fulvestrant in the management of intestinal obstruction associated with
lobular carcinoma has not been specifically described.
Case presentation: Herein we present two cases where fulvestrant, as the only available
parenteral endocrine agent for postmenopausal advanced breast cancer has the opportunity to
provide a means to initiate treatment in those patients who present with varying degrees of
intestinal obstruction.
Conclusion: Fulvestrant may obviate the use of chemotherapy while achieving sustained clinical
benefit with less toxicity, in appropriately selected patients.
Background
Fulvestrant (Faslodex) is a relatively new oestrogen recep-
tor (ER) antagonist with a novel mode of action; it binds,
blocks, and increases degradation of ER [1].
Fulvestrant is licensed for treatment of postmenopausal
women with hormone receptor-positive advanced breast
cancer (HR(+) ABC) progressing or recurring on anti-oes-
trogen therapy. However, it is also active in the first-line
setting in patients with HR(+) tumours [1]. It is currently
the only parenteral endocrine agent licensed for use in
postmenopausal breast cancer, given as 250 mg intramus-
cularly every 4 weeks.
The role of fulvestrant in the management of intestinal
obstruction associated with lobular carcinoma has not
been specifically described. Herein we present two cases –
both highlighting the use of fulvestrant in this context.
Case presentation
Case 1
An 82 year old lady presented as an emergency with small
bowel obstruction but no history of abdominal surgery.
Her chest X-ray revealed a small pleural effusion at the
right base. Concomitantly, she was found to have a highly
suspicious, palpable mass on her right breast.
CT scan findings revealed obstruction at the distal ileum
(Figure 1), bilateral hydronephroses, widespread sclerotic
bony metastases and a pulmonary embolus (PE). The
right-sided breast mass was biopsied and this confirmed
an invasive lobular adenocarcinoma (Grade 2), that was
both strongly ER and progesterone receptor (PR) positive,
with a H-score of 280 and 220 respectively.
She was deemed high risk for surgery due to her recent PE
and she also did not wish to have surgery. In view of the
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circumstances, she was commenced on fulvestrant injec-
tions as a primary endocrine therapy.
This lady's intestinal obstruction eventually settled with
non-operative management. When she was reviewed in
the outpatient clinic two months after commencing ful-
vestrant, her tumour marker (CA15.3) had decreased
from 57 to 38 kU/L. Follow-up CT scan at 6 months
showed no evidence of progression of metastases with res-
olution of the small bowel obstruction.
At one year of fulvestrant, the overall assessment was that
of a partial response with complete resolution of the pal-
pable breast tumour.
Case 2
With a background history of ER+ lobular breast carci-
noma metastasizing to the lungs and bones for a few
years, a 64 year old lady presented recently with symp-
toms of gastric outlet obstruction and changes in bowel
habit.
This patient was first diagnosed with ER+ lobular breast
carcinoma and was treated with wide local excision and
post-operative radiotherapy. She then developed recur-
rences in her lymph node which progressed to her lungs
and bones over the years.
CT scan revealed thickening in the duodenum and in both
the ascending and descending colon with narrowing of
the lumen (Figure 2). Biopsy results from both the duode-
num and colon were consistent with metastases from a
breast primary. Her symptoms of gastric outlet obstruc-
tion resolved after an uneventful gastrojejunostomy but
her bowel symptoms remained. She was commenced on
fulvestrant as systemic therapy following prior treatments
with tamoxifen, then an aromatase inhibitor.
A repeat CT done 2 months later showed stable disease.
She felt very well in herself with resolution of her bowel
symptoms.
Discussion
Lobular breast carcinoma accounts for about 8% to 14%
of all breast cancers [2]. Several studies have demon-
CT scan demonstrating mechanical small bowel obstruction Figure 1
CT scan demonstrating mechanical small bowel obstruction.World Journal of Surgical Oncology 2008, 6:128 http://www.wjso.com/content/6/1/128
Page 3 of 4
(page number not for citation purposes)
strated higher prevalence of spread of metastatic disease to
the gastrointestinal tract, peritoneum and retroperito-
neum, and ovaries in patients when compared to patients
with ductal carcinoma [3,4]. Loss of expression of the cell-
cell adhesion molecule E-cadherin in infiltrating lobular
carcinoma may have contributed to these differences [5].
In hormone-responsive patients, endocrine therapy repre-
sents the mainstay of effective, well-tolerated treatment
for advanced breast cancer before cytotoxic chemotherapy
is required. A proviso for the success of any new endocrine
therapy must be a lack of cross-resistance with prior treat-
ments [6]. It is found that women who respond well to
endocrine treatment for sustained periods tend to
respond well to subsequent endocrine therapy. In Case 2,
there was a decrease in the time lag between each endo-
crine therapy prior to starting fulvestrant. However, as
noted, the patient responded well to treatment, obviating
the need to commence chemotherapy.
This case report highlights not only the unusual presenta-
tion (ie intestinal obstruction) known to be associated
with lobular carcinomas [2,5] but also the challenges this
specific type poses to initiating therapy. In the presence of
gastric metastasis, it is found that endocrine therapy
(tamoxifen as a first line agent) is used as often as chemo-
therapy [7]. The chemotherapy schemes most frequently
used were cyclophosphamide, methotrexate and 5 fluor-
ouracil or cytoxan, doxorubicin and 5 fluorouracil. Initiat-
ing tamoxifen was not an option in Case 1 and fulvestrant
proved to be an efficacious alternative.
A recent study demonstrated that fulvestrant was active in
patients with multiple sites of metastases, visceral metas-
tases, human epidermal growth factor receptor 2-positive
disease and after heavy endocrine pre-treatment [8].
Another study comparing fulvestrant with anastrozole
appears to show that patients with visceral metastases may
have a longer duration of response with fulvestrant [9].
Two large randomized trials have previously shown that
fulvestrant is at least as effective as anastrozole against
breast cancer in postmenopausal women who failed on
prior endocrine therapy [10,11]. However, fulvestrant
CT scan demonstrating thickening of colonic wall with narrowing of lumen Figure 2
CT scan demonstrating thickening of colonic wall with narrowing of lumen.Publish with BioMed Central    and   every 
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showed neither superiority nor noninferiority in compar-
ison to tamoxifen for the treatment of postmenopausal
women who have received no prior hormonal or cytotoxic
therapy for advanced breast cancer [12].
Conclusion
Fulvestrant, is the only available parenteral endocrine
agent for postmenopausal advanced breast cancer, and
has the opportunity to provide a means to initiate treat-
ment in patients who present with varying degrees of
intestinal obstruction. This may obviate the use of chem-
otherapy while achieving sustained clinical benefit, with
less toxicity, in appropriately selected patients.
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